This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holland, D. T. Articles by Morse, G. D. Search for Related Content PubMed PubMed Citation Articles by Holland, D. T. Articles by Morse, G. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2004, p. 824-831, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.824-831.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories

Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group, Division of AIDS, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland

Received 15 July 2003/ Returned for modification 18 September 2003/ Accepted 2 December 2003

Clinical trials designed to compare antiretroviral regimens, investigate therapeutic drug monitoring, or measure pharmacometrics often include protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, requiring the measurement of these antiretrovirals in plasma. Within the adult and pediatric AIDS Clinical Trials Group (ACTG), a network of Pharmacology Support Laboratories (PSLs) is a component of the group laboratory infrastructure and conducts these types of pharmacologic assays. The adult ACTG has developed a comprehensive quality assurance program for the conduct of clinical pharmacology protocols, one component of which is the antiretroviral proficiency testing (PT) program that has been implemented between the adult and pediatric pharmacology laboratories of the ACTG. PT testing samples were prepared and distributed in July 2001, February 2002, and July 2002. High, medium, and low concentrations of PIs (indinavir, saquinavir, amprenavir, lopinavir, ritonavir, and nelfinavir) and NNRTIs (nevirapine and efavirenz) were added to drug-free EDTA plasma and distributed, on dry ice, to eight ACTG PSLs. One testing laboratory used liquid chromatography-tandem mass spectrometry, and seven used high-performance liquid chromatography-UV analysis. A result was considered acceptable if it was within 20% deviation of the assigned concentration. For all concentrations of PIs evaluated, 96% of samples tested (430 of 448 measurements) met the acceptance criteria. For both NNRTIs, 100% of samples tested (140 of 140 measurements) met the acceptance criteria. In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials.

This article has been cited by other articles:

• Hammer, S. M., Eron, J. J. Jr, Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., Jacobsen, D. M., Montaner, J. S. G., Richman, D. D., Yeni, P. G., Volberding, P. A. (2008). Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel. JAMA 300: 555-570 [Abstract] [Full Text]  
• Durand-Gasselin, L., Pruvost, A., Dehee, A., Vaudre, G., Tabone, M.-D., Grassi, J., Leverger, G., Garbarg-Chenon, A., Benech, H., Dollfus, C. (2008). High Levels of Zidovudine (AZT) and Its Intracellular Phosphate Metabolites in AZT- and AZT-Lamivudine-Treated Newborns of Human Immunodeficiency Virus-Infected Mothers. Antimicrob. Agents Chemother. 52: 2555-2563 [Abstract] [Full Text]  
• Morse, G. D., Rosenkranz, S., Para, M. F., Segal, Y., DiFrancesco, R., Adams, E., Brizz, B., Yarasheski, K. E., Reichman, R. C., the ACTG 5043 Protocol Team, (2005). Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals. Antimicrob. Agents Chemother. 49: 3373-3381 [Abstract] [Full Text]